Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
International Journal of Medicinal Mushrooms
Impact-faktor: 1.423 5-jähriger Impact-Faktor: 1.525 SJR: 0.431 SNIP: 0.661 CiteScore™: 1.38

ISSN Druckformat: 1521-9437
ISSN Online: 1940-4344

Volumes:
Volumen 22, 2020 Volumen 21, 2019 Volumen 20, 2018 Volumen 19, 2017 Volumen 18, 2016 Volumen 17, 2015 Volumen 16, 2014 Volumen 15, 2013 Volumen 14, 2012 Volumen 13, 2011 Volumen 12, 2010 Volumen 11, 2009 Volumen 10, 2008 Volumen 9, 2007 Volumen 8, 2006 Volumen 7, 2005 Volumen 6, 2004 Volumen 5, 2003 Volumen 4, 2002 Volumen 3, 2001 Volumen 2, 2000 Volumen 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v13.i4.10
pages 319-326

Supplementation with a Soluble Beta-Glucan Exported from Shiitake Medicinal Mushroom, Lentinus edodes (Berk.) Singer Mycelium: a Crossover, Placebo-Controlled Study in Healthy Elderly

Jean-Michel Gaullier
Link Medical Research AS, POBox 4382 Nydalen, 0402 Oslo, Norway
Jowita Sleboda
Link Medical Research AS, POBox 4382 Nydalen, 0402 Oslo, Norway
Erik Snorre Ofjord
CENCLIN, Gamlehaugsveien 20, N-5231 Paradis, Norway
Elling Ulvestad
Laboratory of Microbiology and Immunology, Haukeland hospital, N-5021 Bergen, Norway
Minna Nurminiemi
Link Medical Research AS, POBox 4382 Nydalen, 0402 Oslo, Norway
Cecilie Moe
Link Medical Research AS, POBox 4382 Nydalen, 0402 Oslo, Norway
Tor Albrektsen
Glycanova
Ola Gudmundsen
Link Medical Research AS, POBox 4382 Nydalen, 0402 Oslo, Norway

ABSTRAKT

Lentinus edodes (Shiitake) is a medicinal mushroom with a long tradition of use in Asia. The major active substance in L. edodes is a (1-6,1-3)-beta-glucan (lentinan). No clinical controlled studies have yet investigated the effect of orally administered lentinan on the immune response in healthy, elderly Caucasian subjects. We evaluated the effect and the safety of a beta-glucan from L. edodes mycelium, Lentinex®, in healthy, elderly subjects in a double blind, crossover, placebo-controlled trial. Forty-two subjects were randomly allocated to two groups given orally either 2.5 mg/day Lentinex® or placebo for 6 weeks; then after a washout period of 4 weeks, the alternate supplementation was given for 6 weeks. The changes in the number of B-cells were significantly different between the groups. The number of NK cells increased significantly in both groups, but there was no significant difference between the groups. Other factors of the immune response (immunoglobulins, complement proteins, cytokines) were not altered. The safety blood variables (differential cell count, liver function, kidney function, and other blood chemistry) were not influenced by Lentinex®, and the number, nature, and severity of adverse events were similar to placebo. Lentinex® given orally to elderly subjects was safe and induced an increase in the number of circulating B-cells.